JPS5881779A - Cultivation method of human lymphoblastic cell - Google Patents

Cultivation method of human lymphoblastic cell

Info

Publication number
JPS5881779A
JPS5881779A JP56180005A JP18000581A JPS5881779A JP S5881779 A JPS5881779 A JP S5881779A JP 56180005 A JP56180005 A JP 56180005A JP 18000581 A JP18000581 A JP 18000581A JP S5881779 A JPS5881779 A JP S5881779A
Authority
JP
Japan
Prior art keywords
cells
culture
glucose
medium
culture medium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP56180005A
Other languages
Japanese (ja)
Inventor
Wataru Nakamatsu
亘 中松
Yoshitoshi Takano
高野 佐敏
Naoki Nishimura
直樹 西村
Hiroshiro Shibai
柴井 博四郎
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ajinomoto Co Inc
Original Assignee
Ajinomoto Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Co Inc filed Critical Ajinomoto Co Inc
Priority to JP56180005A priority Critical patent/JPS5881779A/en
Publication of JPS5881779A publication Critical patent/JPS5881779A/en
Pending legal-status Critical Current

Links

Landscapes

  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

PURPOSE:To prevent the reduction in the number of living cells in the end of a cell multiplication period and obtain stably the living cells, by cultivating human lymphoblastic cells in a culture medium containing glucose added thereto. CONSTITUTION:In clutivating human lymphoblastic cells by the conventional method, glucose is added to a culture medium of the oridinary composition from the initial period of the cultivation or in the course of the clutivation. In case the pH of the culture medium is reduced, the pH is adjusted by a means, e.g. increasing the concentration of sodium hydrogencarbonate or reducing the partial pressure of gaseous carbon dioxide in the vapor phase, etc.

Description

【発明の詳細な説明】 本発明は、ヒトリンパ芽球様細胞の培養方法に関する。[Detailed description of the invention] The present invention relates to a method for culturing human lymphoblastoid cells.

ヒトリンパ芽球様細胞はほとんどがヒト白血病患者から
分離されるものである。たとえば、ヒト白血病患者の血
液を採血後リンパ球を分画し、リンパ芽球様細胞を分離
する。これらリンパ芽球様細胞は、リンフ才力インの研
究手段として近年利用されるようになってきた。たとえ
ば、Tcell型リンパ芽球様細胞株をCon A等の
幼若化因子で処理することによりインターロイキン−2
(以下、[t t、 −,2Jと略記する。)等のリン
フ才力インが生産されることが明らかになった。
Most human lymphoblastoid cells are isolated from human leukemia patients. For example, after collecting blood from a human leukemia patient, lymphocytes are fractionated and lymphoblastoid cells are separated. These lymphoblastoid cells have recently come to be used as a research tool for lymphogenesis. For example, by treating Tcell-type lymphoblastoid cell lines with blastogenesis factors such as Con A, interleukin-2
(Hereinafter, abbreviated as [t t, -, 2J), etc., were found to be produced.

そこで、本発明者は、T cell型リンパ芽球様細胞
を用いてIL−2の細胞培養による生産を試みた。
Therefore, the present inventor attempted to produce IL-2 by cell culture using T cell type lymphoblastoid cells.

IL−2の細胞培養−こよる生産は2つのステップから
成る。1つは、細胞の大量培養であり、他方は、得られ
た細胞を適当な条件下に移してIL−2を生産せしめる
ことである。
Cell culture-based production of IL-2 consists of two steps. One is mass culture of cells, and the other is to transfer the obtained cells under appropriate conditions to produce IL-2.

現在のところ、前者の問題を解決するべき、T cel
l型リンパ芽球様細胞の大量培養に関する報告は見られ
ない。本発明者は、Tcell型リンパ芽球様細胞を通
常の浮遊性動物細胞の培養法に従い、RPMI−164
0培地を用いて培養したところ、細胞の増殖が進み生細
胞数が106個/ m1前後になった時点で急激に生細
胞数が°減少することを観察した。この現象は、次のI
 ’L −2の生産のための細胞調製ということかち+
やと培尊管理上問題が多い。
At present, T cel should solve the former problem.
There are no reports regarding large-scale culture of type I lymphoblastoid cells. The present inventor cultivated Tcell-type lymphoblastoid cells using RPMI-164 according to the usual culture method for planktonic animal cells.
When the cells were cultured using 0 medium, it was observed that the number of viable cells rapidly decreased when cell proliferation progressed and the number of viable cells reached around 106 cells/ml. This phenomenon is explained by the following I
'Cell preparation for L-2 production +
There are many problems in management of Yato Kaison.

そこで、この現象をなくするための条件を検討したとこ
ろ、培地中にグルコースを補添することにより、培養後
期の生細胞数の減少を防ぐことができることを見出した
。即ち、ヒトT eell型リンパ芽球様細胞株を用い
て溶存酸素の挙動、培地成分の消費速度等を調べたとこ
ろ、グルコース、グルタミンが培養中1こ急速に減少す
ること、特1こグルコースは生細胞数の減少がはじまる
時期と残存グルコースが01こなる時期が一致すること
を見出し、これらの補添効果tこついて検討した。
Therefore, we investigated the conditions to eliminate this phenomenon and found that by supplementing the culture medium with glucose, it was possible to prevent the decrease in the number of living cells in the later stages of culture. That is, when we investigated the behavior of dissolved oxygen, the consumption rate of medium components, etc. using a human T-eell lymphoblastoid cell line, we found that glucose and glutamine rapidly decreased during culture, and that glucose in particular It was found that the time when the number of living cells begins to decrease and the time when the residual glucose level reaches 01% coincides with each other, and the supplementary effects of these were investigated.

その結果、グルコース補添により生細胞数減少を防げる
ことが判明した。また、生細胞減少予防の見地からは、
グルコースは培養の初めから培地1こ補添してもよいし
、途中で補添してもよいことも判明した。補添量は生細
胞数の減少を部分的側こまたけ完全に防止できる量であ
ればよく、他の条件を同じ1こしてグルコースを補添し
た場合が補添しない場合t″−−比較生細胞tが多けれ
ば、これはグルコース補添の効果というべく、このよう
な場合は全て本発明の範囲内である。
As a result, it was found that glucose supplementation could prevent a decrease in the number of viable cells. Also, from the perspective of preventing the decrease of viable cells,
It has also been found that glucose may be supplemented to one portion of the medium from the beginning of the culture, or may be supplemented midway through the culture. The amount of supplementation may be any amount that can partially and completely prevent the decrease in the number of viable cells. If the number of cells t is large, this is an effect of glucose supplementation, and all such cases are within the scope of the present invention.

本発明の方法で培養できるヒトリンパ芽球様細胞株とし
ては、たとえば、急性リンパ性白血病、慢性リンパ性白
血病患者から分離したリンパ芽球様細胞をあげることが
できる(山村雄−他編「ガン」共立出版(1978))
。これらの白血病細胞はウィルストランスフオーム型か
否かについては明らかではないが、京大つィルス研日沼
らは成人’i’ cell型白血病細胞を用いて検討し
た結果、レトロウィルス様粒子を見出している(第29
回日本ウィルス学会(1981年)演題抄録2025)
Human lymphoblastoid cell lines that can be cultured by the method of the present invention include, for example, lymphoblastoid cells isolated from patients with acute lymphocytic leukemia and chronic lymphocytic leukemia (Yamamura et al., ed. "Cancer"). Kyoritsu Publishing (1978))
. It is not clear whether these leukemia cells are of the viral transform type, but Hinuma et al. of the Institute for Virus Research, Kyoto University conducted an investigation using adult 'i' cell type leukemia cells and found retrovirus-like particles. There is (29th
Annual Japanese Society of Virology (1981) abstract 2025)
.

もちろん、本発明の方法で培養できるヒドリン・(芽球
様細胞株は上1こ例示のもの1こ限られるわけではない
Of course, the hydrin-blast-like cell lines that can be cultured by the method of the present invention are not limited to the above-mentioned examples.

ヒドリ/パ芽球様細胞を培養する際をこ用いる基本培地
としては以下のような通常の培地でよい。
As the basic medium used for culturing Hidori/Papoblastoid cells, the following ordinary medium may be used.

E−MEM (Eagle’s mjnimurn e
ssential medium)。
E-MEM (Eagle's mjnimurne e
ssential medium).

D−MEM (Dulbecco modi(ied 
Eagl@’s minimumessential 
 medium  )  、  RPMI  −164
0(Roswell−Park Memorial I
n5titute  1640 )+D−MEM  を
改変し無血清状態で細胞生育を可・能tこしたRITC
55−9(日本免疫学会編「免疫実験操作法」9巻30
58頁(1980))等である。
D-MEM (Dulbecco modi(ied)
Eagle@'s minimum essential
medium), RPMI-164
0 (Roswell-Park Memorial I
RITC modified from n5 titute 1640)+D-MEM to enable cell growth in serum-free conditions
55-9 (edited by the Japanese Society of Immunology, “Immunology Experimental Procedures”, Vol. 9, 30)
58 (1980)).

ヒトリンパ芽μ様細胞の培養方法もまた、通常の方法で
よい。即ち、培養試験管を垂直から5°の角度に傾けて
設置された円板1こ差し込み恒温状態で回転させる回転
培養法、一定半径の水平運動を行なう板上に培養フラス
コをセットし恒温状態で旋回させる旋回培養法、及び培
養槽内1こ攪拌子を入れて培養液を攪拌したから培養す
る攪拌培養法(スピンナー培養法)等がある。なお、細
胞によってはグルコース補添培地では生育に併ないpH
が低下する場合があるが、その場合は培地中N a H
CO3濃度を高めるあるいは気相炭鍛ガス分圧を下げる
等の方法によりpH調節をするとよい。
A conventional method for culturing human lymphoblast μ-like cells may also be used. In other words, a rotary culture method in which a culture test tube is inserted into a disc tilted at an angle of 5 degrees from the vertical and rotated in a constant temperature state, and a culture flask is set on a plate that moves horizontally with a constant radius and is kept in a constant temperature state. There is a spinning culture method in which the culture is swirled, and a stirring culture method (spinner culture method) in which a stirrer is placed in the culture tank to stir the culture solution and then cultured. In addition, depending on the cell, the pH may change due to growth in glucose-supplemented medium.
may decrease, but in that case, NaH in the medium
It is preferable to adjust the pH by increasing the CO3 concentration or lowering the partial pressure of vapor-phase coal forging gas.

以下、実施例によりさら1こ詳しく本発明を説明する。Hereinafter, the present invention will be explained in more detail with reference to Examples.

実施例1 ヒトTcell型リンパ芽球型白血病細胞を0.9×1
06個/ meになるようtこ培地25xlにけん濁し
た。
Example 1 Human Tcell type lymphoblastic leukemia cells at 0.9 x 1
The cells were suspended in 25xl of tuna medium at a concentration of 0.6 cells/me.

コjtf内容t25011/のプラスチックフラスコ(
FaIcon  3024 )中、37C1キヤツプ半
開放状態で5%炭酸ガス気流下培養した。培地はRPM
I−1640にNaHCOs  2 m1g/ ml 
、ペニシリン50ユニツト/ we 、ストレプトマイ
シン50μf/lI/、牛胎児血清10%を添加した通
常培地もしくはさら1こグルコース(2w、g /wt
l )を補添した培地を用いた。
Cojtf contents T25011/Plastic flask (
The cells were cultured in FaIcon 3024) under a 5% carbon dioxide gas stream with the 37C1 cap semi-open. Medium is RPM
I-1640 with NaHCOs 2ml 1g/ml
, 50 units of penicillin/we, 50 μf/l of streptomycin, normal medium supplemented with 10% fetal bovine serum or 1 g/w of glucose (2w, g/wt).
A medium supplemented with 1) was used.

培養時間と生細胞数の関係を第1図に示す。これより、
グルコース補添培地では通常培地に比して生細胞の減少
をi止するのみならずむしろ生細胞の増加が見られ、安
定的1こ生細胞を得ることができることがわかる。
The relationship between culture time and number of living cells is shown in Figure 1. Than this,
Compared to the normal medium, the glucose-supplemented medium not only stopped the decrease in the number of living cells, but actually increased the number of living cells, indicating that it was possible to stably obtain single living cells.

実施例2 実施例1の方法においてグルコース補添量をo、s m
g 7wt11t、o mg /me、  2 mg 
7d−13叩/−と変化させたときの培養7日目の生細
胞数を測定した。結果は第1表に示すとおりであった。
Example 2 In the method of Example 1, the amount of glucose supplemented was o, s m
g 7wt11t, o mg/me, 2 mg
The number of viable cells was measured on the 7th day of culture when the culture was changed to 7d-13/-. The results were as shown in Table 1.

第  1  表Table 1

【図面の簡単な説明】[Brief explanation of the drawing]

第1、図は、培養後期における細胞死滅ケこたいするグ
ルコース補添効果を示す。○は通常培地、△は通常培地
1こグルコース(2,0my/me )補添添地での結
果を示す。 特許出願人 味の素株式会社 第1図
The first figure shows the effect of glucose supplementation on cell death in the late stage of culture. ◯ indicates the results obtained using normal medium, and △ indicates the results obtained using normal medium supplemented with 1 glucose (2.0 my/me 2 ). Patent applicant Ajinomoto Co., Inc. Figure 1

Claims (1)

【特許請求の範囲】[Claims] ヒトリンパ芽球様細胞の培養において、通常の培地組成
に対しさらにグルコースを補添した培地を用いることに
より細胞増殖終期における生細胞の減少を防止すること
を特徴とするリンパ芽球様細胞の培養方法。
A method for culturing human lymphoblastoid cells, which comprises preventing a decrease in viable cells at the final stage of cell proliferation by using a medium supplemented with glucose in addition to the normal medium composition. .
JP56180005A 1981-11-10 1981-11-10 Cultivation method of human lymphoblastic cell Pending JPS5881779A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP56180005A JPS5881779A (en) 1981-11-10 1981-11-10 Cultivation method of human lymphoblastic cell

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP56180005A JPS5881779A (en) 1981-11-10 1981-11-10 Cultivation method of human lymphoblastic cell

Publications (1)

Publication Number Publication Date
JPS5881779A true JPS5881779A (en) 1983-05-17

Family

ID=16075784

Family Applications (1)

Application Number Title Priority Date Filing Date
JP56180005A Pending JPS5881779A (en) 1981-11-10 1981-11-10 Cultivation method of human lymphoblastic cell

Country Status (1)

Country Link
JP (1) JPS5881779A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04113502U (en) * 1991-03-26 1992-10-05 太陽鍛工株式会社 Tilling claw support means

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04113502U (en) * 1991-03-26 1992-10-05 太陽鍛工株式会社 Tilling claw support means

Similar Documents

Publication Publication Date Title
US5888807A (en) Devices for maintaining and growing human stem and/or hematopoietics cells
US5670147A (en) Compositions containing cultured mitotic human stem cells
AU685743B2 (en) Methods, compositions and devices for maintaining and growing human stem and/or hematopoietic cells
US20040063201A1 (en) Methods for regulating the specific lineages of cells produced in a human hematopoietic cell culture, methods for assaying the effect of substances of lineage-specific cell production, and cell compositions produced by these cultures
JPH078274A (en) Method and device for improving substance transfer in film bioreactor
EA199800835A1 (en) Culture medium of mammalian cells, process for its preparation and a mixture of components, compositions, methods of preparation, production of clonal growth, reproduction and altered phenotype of hepatocytes IN VITRO, CELLS, PHARMACEUTICAL COMPOSITION AND METHODS FOR recombinant cells and gene product, by use of cells, a method of transplanting hepatocytes , METHOD FOR TESTING A MEDICAL PREPARATION, METHOD FOR MAINTAINING THE VIABILITY OF DIFFERENTIATED HEPATOCYTES
Koenig et al. Immune suppression of erythropoiesis in transient erythroblastopenia of childhood
US20040224401A1 (en) Physiochemical culture conditions for embryonic stem cells
Pierson et al. Production of human natural killer cells for adoptive immunotherapy using a computer-controlled stirred-tank bioreactor
Paul Quiescent SV40 virus transformed 3T3 cells in culture
Ziegler et al. The propagation of mammalian cells in a 20-liter stainless steel fermentor
CN111748527B (en) Chemical component limited efficient feeding culture medium and preparation method and application thereof
JPS5881779A (en) Cultivation method of human lymphoblastic cell
CN106754658A (en) A kind of culture medium for cultivating dental pulp stem cell and preparation method thereof
Lichtman et al. Vitamin B12b: Some Properties and its Therapeutic Use.
CA2090677A1 (en) Method for culturing t lineage precursor cells
CN108913647B (en) Stem cell culture medium and preparation method thereof
Socransky et al. Replacement of ascitic fluid or rabbit serum requirement of Treponema dentium by alpha-globulin
CN105695400A (en) Serum-free medium for purifying myocardial cells of stem cell sources
Levere et al. Steroid metabolites and the control of hemoglobin synthesis.
US5468635A (en) In vitro method for stimulating cell growth by culturing cells in a serum-free culture medium comprising human lysozyme
Rasmussen On the role of food vacuole formation in the uptake of dissolved nutrients by Tetrahymena
Zimmerman et al. Relationship between structure of phenothiazines and in vitro cytotoxicity
Hauke et al. Reticulocytopenia in severe autoimmune hemolytic anemia (AIHA) of the warm antibody type
CN106754678A (en) A kind of culture medium suitable for dental pulp stem cell in vitro culture and preparation method thereof